AI-industrie.png

Smart Manufacturing & Materials-iStock-1135159658-BEWERKT.jpg

The Nijmegen-based company Aiosyn is developing a diagnostic platform that uses AI to help pathologists make more accurate and efficient clinical diagnoses. Oost NL invested in the company in 2022 through ION+.<img src="https://cms.aihub-oost.nl/uploads/Z73k01v_P56x_Wbwhfa_W_Vve5_Yzhgu6kyaqi9h_B_Mkth_a2dea6cb60.jpeg" alt="Z73k01vP56xWbwhfaWVve5Yzhgu6kyaqi9hBMkth.jpeg" srcset="https://cms.aihub-oost.nl/uploads/thumbnail_Z73k01v_P56x_Wbwhfa_W_Vve5_Yzhgu6kyaqi9h_B_Mkth_a2dea6cb60.jpeg 245w,https://cms.aihub-oost.nl/uploads/small_Z73k01v_P56x_Wbwhfa_W_Vve5_Yzhgu6kyaqi9h_B_Mkth_a2dea6cb60.jpeg 500w," sizes="100vw" width="612" height="198">Pathology is indispensable in the diagnostic process for many diseases, such as cancer. Currently, tissue examination is performed using a microscope. Globally, there is a shortage of pathologists and a growing demand for efficiency and consistent quality in the assessment of images. The diagnosis made has a major impact on the treatment to be followed. The better the diagnosis, the better the patient can ultimately be helped. Aiosyn’s AI-based platform assists pathologists in this process.Aiosyn originated from the Computational Pathology Group at Radboud University Medical Center (Radboudumc), led by Jeroen van der Laak (CSO of Aiosyn). The technology uses a powerful form of “neural networks” to identify abnormal tissue patterns, such as cancer, with unprecedented accuracy. Aiosyn aims to bring these algorithms from the research field into clinical practice to improve the speed and quality of diagnostics in pathology. The Aiosyn team will use the investment to expand pathologists’ access to artificial intelligence.

Aiosyn is developing a platform to support pathologists

These entrepreneurs have paved the way for you

Meet our frontrunners

Aiosyn.jpg

The Nijmegen-based company Aiosyn is developing a diagnostic platform that uses AI to help pathologists make more accurate and efficient clinical diagnoses. Oost NL invested in the company in 2022 through ION+.&nbsp;